JUL 13, 2018 01:49 PM PDT

Pharmacological Strategy Attempts To Treat Multiple Symptoms of Fragile X

WRITTEN BY: Nouran Amin

Recent research in a mouse model of fragile X syndrome (FXS), scheduled for publication in Neuropsychopharmacology, shows that a pharmacological strategy can reduce multiple behavioral and cellular deficiencies in the most common inherited form of intellectual disability and a major single-gene cause of autism spectrum disorders.

When a compound, by the name GSK6A, was given to mice lacking the Fmr1 gene, an established animal model of fragile X syndrome, symptomatic behaviors were alleviated including impaired social interactions and decision making, displayed by individuals with fragile X syndrome.

Results showed that treatment with GSK6A, an inhibitor of a cellular signaling enzyme called p110β form of PI3 (phosphoinositide-3) kinase, may serve as a logical strategy for treating cognitive and behavioral problems in fragile X syndrome; the efficacy, of course, would be evaluated in human clinical trials.

"Our results suggest that p110β inhibitors can be repurposed for fragile X syndrome, and they have implications for other subtypes of autism spectrum disorders that are characterized by similar alterations of this pathway," says Gary Bassell, Ph.D., professor and chair of cell biology at Emory University School of Medicine. "Right now, no proven effective treatments are available for fragile X syndrome that are targeted to the disease mechanism," Gross says. "We think that p110β is an appropriate target because it is directly regulated by FMRP, and it is overactivated in both mouse models and patient cell lines."

To ensure that undesirable side-effects of the pharmacological strategy do not appear, the researchers are first planning long-term animal studies on p110β inhibitors in fragile X syndrome.

1 in 3000 males and 1 in 6000 females are affected with Fragile X and females often have milder symptoms. Affected children may display intellectual disability with a delay of milestones such as speech. They may also feature autism-like features including impaired social skills, gaze aversion/social anxiety, hyperactivity and repetitive behaviors.

FXS is a result the silencing of a single gene, FMR1, which prevents the production of an RNA binding protein known as FMRP. FMRP manages the production of several proteins at synapses, the sites of communication between neurons.

In the current study, short-term treatments are only considered which covers one or two injections. For one experiment, mice were treated for 10 days, which normalized their densities of dendritic spines present in the hippocampus. Synaptic structures are overabundant in the absence of FMRP in animals and humans with FXS.

"It is likely that PI3 kinase—in its various forms—needs to be kept in a tight balance at the synapse," Bassell says. "Too much or too little can tip things into a suboptimal zone, especially for complex behaviors. We think targeting the excess p110β in FXS can restore signaling between upstream and downstream defects linked to the absence of FMRP. We can't use mouse behavioral tests alone to understand a drug's effects," Bassell says. "It is critical to have molecular, cellular and neurophysiological phenotypes, which we and others do."

Source: Journal of Neuropsychopharmacology, Science Daily, Medical Xpress

 

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUN 06, 2018
Drug Discovery
JUN 06, 2018
Computer Simulations Offer Alternative Methods for Diabetic Drugs
The Governor's Chair for Molecular Biophysics at the University of Tennessee (Knoxville), Jeremy Smith, and the director for the Center for Molecular B...
JUN 27, 2018
Drug Discovery
JUN 27, 2018
Drug Reduces Hearing Loss in Children Treated for Hepatoblastoma
Children treated for hepatobalstoma, a rare childhood liver cancer, often experience hearing loss when undergoing a type of chemotherapy known as cisplatin...
JUL 30, 2018
Genetics & Genomics
JUL 30, 2018
Therapeutic Created for a Rare Genetic Disease
There is new hope for people that suffer from a rare genetic disease called Hereditary angioedema (HAE)....
JUL 31, 2018
Drug Discovery
JUL 31, 2018
Two Molecules Identified For Treating Traumatic Brain Injury (TBI)
Scientists at Rutgers University have discovered two molecules that protect nerve cells, serving as motivation to develop new drugs for brain damage. The d...
AUG 15, 2018
Drug Discovery
AUG 15, 2018
Peripheral Nerve Blockers Treat Facial Pain
A new research study published American Journal of Emergency Medicine explains the use of peripheral nerve inhibitors in the treatment of facial pain condi...
AUG 27, 2018
Drug Discovery
AUG 27, 2018
Anemic Drug Re-purposed To Treat Heart Failure in Diabetics
According to a study funded by the British Heart Foundation (BHF) and Diabetes UK, drugs in development to treat anemia can now be repurposed to help preve...
Loading Comments...